Extended-release guanfacine hydrochloride in 6-17-year olds with ADHD: a randomised-withdrawal maintenance of efficacy study.

BACKGROUND Extended-release guanfacine hydrochloride (GXR), a selective α2A-adrenergic agonist, is a nonstimulant medication for attention-deficit/hyperactivity disorder (ADHD). This phase 3, double-blind, placebo-controlled, randomised-withdrawal study evaluated the long-term maintenance of GXR efficacy in children/adolescents with ADHD. METHODS Children/adolescents (6-17 years) with ADHD received open-label GXR (1-7 mg/day). After 13 weeks, responders were randomised to GXR or placebo in the 26-week, double-blind, randomised-withdrawal phase (RWP). The primary endpoint was the percentage of treatment failure (≥50% increase in ADHD Rating Scale version IV total score and ≥2-point increase in Clinical Global Impression-Severity compared with RWP baseline, at two consecutive visits). The key secondary endpoint was time to treatment failure (TTF). TRIAL REGISTRATION ClinicalTrials.gov identifier NCT01081145; EudraCT 2009-018161-12. RESULTS A total of 528 participants enrolled; 316 (59.8%) entered the RWP. Treatment failure occurred in 49.3% of the GXR and 64.9% of the placebo group (p = 0.006). TTF was significantly longer in GXR versus placebo (p = 0.003). GXR was well tolerated. CONCLUSIONS Guanfacine hydrochloride demonstrated long-term maintenance of efficacy compared with placebo in children/adolescents with ADHD. Implications of the placebo substitution design and findings with different ADHD medications are discussed.

[1]  Lynn R. Zakeri.  ADHD Rating Scale-5 for Children and Adolescents: Checklists, Norms, and Clinical Interpretation , 2017 .

[2]  M. Kosinski,et al.  Psychometric validation of the Weiss Functional Impairment Rating Scale-Parent Report Form in children and adolescents with attention-deficit/hyperactivity disorder , 2015, Health and Quality of Life Outcomes.

[3]  B. Robertson,et al.  Efficacy and safety of extended-release guanfacine hydrochloride in children and adolescents with attention-deficit/hyperactivity disorder: A randomized, controlled, Phase III trial , 2014, European Neuropsychopharmacology.

[4]  F. Sallee,et al.  Attention-Deficit/Hyperactivity Disorder with Inadequate Response to Stimulants: Approaches to Management , 2014, CNS Drugs.

[5]  J. Dreyhaupt,et al.  Atomoxetine affects transcription/translation of the NMDA receptor and the norepinephrine transporter in the rat brain – an in vivo study , 2013, Drug design, development and therapy.

[6]  C. Propper,et al.  Pre-school hyperactivity/attention problems and educational outcomes in adolescence: prospective longitudinal study , 2013, British Journal of Psychiatry.

[7]  P. Trzepacz,et al.  Maintenance of response after open-label treatment with atomoxetine hydrochloride in international European and non-European adult outpatients with attention-deficit/hyperactivity disorder: a placebo-controlled, randomised withdrawal study , 2013 .

[8]  D. Goodman.  Sustained treatment effect in attention-deficit/hyperactivity disorder: focus on long-term placebo-controlled randomized maintenance withdrawal and open-label studies , 2013, Therapeutics and clinical risk management.

[9]  F. Sung,et al.  Correlation between Epilepsy and Attention Deficit Hyperactivity Disorder: A Population-Based Cohort Study , 2013, PloS one.

[10]  R. Findling,et al.  Maintenance of efficacy of lisdexamfetamine dimesylate in adults with attention-deficit/hyperactivity disorder: randomized withdrawal design. , 2012, The Journal of clinical psychiatry.

[11]  S. Aryal,et al.  Dose effects and comparative effectiveness of extended release dexmethylphenidate and mixed amphetamine salts. , 2011, Journal of child and adolescent psychopharmacology.

[12]  J. Biederman,et al.  A Randomized, 3-Phase, 34-Week, Double-Blind, Long-Term Efficacy Study of Osmotic-Release Oral System-Methylphenidate in Adults With Attention-Deficit/Hyperactivity Disorder , 2010, Journal of clinical psychopharmacology.

[13]  L. Davis,et al.  Atomoxetine and neuropsychological function in children with attention-deficit/hyperactivity disorder: results of a pilot study. , 2009, Journal of child and adolescent psychopharmacology.

[14]  T. Spencer,et al.  Safety and effectiveness of coadministration of guanfacine extended release and psychostimulants in children and adolescents with attention-deficit/hyperactivity disorder. , 2009, Journal of child and adolescent psychopharmacology.

[15]  J. McGough,et al.  Long-term safety and efficacy of guanfacine extended release in children and adolescents with attention-deficit/hyperactivity disorder. , 2009, Journal of child and adolescent psychopharmacology.

[16]  J. McGough,et al.  Guanfacine extended release in children and adolescents with attention-deficit/hyperactivity disorder: a placebo-controlled trial. , 2009, Journal of the American Academy of Child and Adolescent Psychiatry.

[17]  J. Biederman,et al.  Long-Term, Open-Label Extension Study of Guanfacine Extended Release in Children and Adolescents with ADHD , 2008, CNS Spectrums.

[18]  Q. Lu,et al.  Activation of α2A adrenoceptors alters dendritic spine development and the expression of spinophilin in cultured cortical neurones , 2008, Brain Research.

[19]  J. Biederman,et al.  A Randomized, Double-Blind, Placebo-Controlled Study of Guanfacine Extended Release in Children and Adolescents With Attention-Deficit/Hyperactivity Disorder , 2008, Pediatrics.

[20]  Lawrence Scahill,et al.  alpha2-Adrenergic receptor agonists for the treatment of attention-deficit/hyperactivity disorder: emerging concepts from new data. , 2007, Journal of child and adolescent psychopharmacology.

[21]  J. Buitelaar,et al.  A Randomized, Double-Blind Study of Continuation Treatment for Attention-Deficit/Hyperactivity Disorder After 1 Year , 2007, Biological Psychiatry.

[22]  Z. -M Song,et al.  α2a adrenoceptors regulate phosphorylation of microtubule-associated protein-2 in cultured cortical neurons , 2004, Neuroscience.

[23]  J. Buitelaar,et al.  Relapse prevention in pediatric patients with ADHD treated with atomoxetine: a randomized, double-blind, placebo-controlled study. , 2004, Journal of the American Academy of Child and Adolescent Psychiatry.

[24]  R. D. Hunt,et al.  The Contribution of α2-Noradrenergic Mechanisms to Prefrontal Cortical Cognitive Function: Potential Significance for Attention-Deficit Hyperactivity Disorder , 1996 .

[25]  S. K. Lo,et al.  Reliability and Validity , 2020, International Encyclopedia of Human Geography.

[26]  T. Banaschewski,et al.  Maintenance of efficacy of lisdexamfetamine dimesylate in children and adolescents with attention-deficit/hyperactivity disorder , 2014 .

[27]  C. Shapiro,et al.  Columbia-Suicide Severity Rating Scale (C-SSRS) , 2011 .

[28]  S. West,et al.  A double-blind, placebo-controlled withdrawal trial of dexmethylphenidate hydrochloride in children with attention deficit hyperactivity disorder. , 2004, Journal of child and adolescent psychopharmacology.

[29]  S. West,et al.  ADouble-Blind, Placebo-Controlled Withdrawal Trial of Dexmethylphenidate Hydrochloride in Children with Attention Deficit Hyperactivity Disorder , 2004 .

[30]  O Abou-Zeid,et al.  alpha2a adrenoceptors regulate phosphorylation of microtubule-associated protein-2 in cultured cortical neurons. , 2004, Neuroscience.

[31]  Robert Reid,et al.  Adhd Rating Scale-IV: Checklists, Norms, and Clinical Interpretation , 1998 .

[32]  R. D. Hunt,et al.  The contribution of alpha 2-noradrenergic mechanisms of prefrontal cortical cognitive function. Potential significance for attention-deficit hyperactivity disorder. , 1996, Archives of general psychiatry.